Trialant
Platform
Home
Studies
Other
Contact Us
Terms of Service
Privacy Policy
Toggle Sidebar
Studies
Study
JSON
Overview
Key facts that identify this study and show where it stands today.
Description
What the study is about and why it is being run, in the researchers' own words.
Conditions
The medical conditions and diseases this study investigates.
Interventions
The treatments and procedures being evaluated in this study.
Participation
Who can join this study and the criteria used to decide.
Design
How the study is designed and how its participant groups are organized.
Contacts
The people to reach with questions about this study or how to join it.
Locations
Where the study is run and whether each site is currently recruiting.
Collaborators
The organizations and people involved in this study.
Similar Studies
Other registered studies that closely resemble this one.
Workspace
Home
Studies
Collections
Views
Contact Us
Terms of Service
Privacy Policy
Sign up
NCT05210894
Expanded Access for Abatacept
NCT05170672
No longer available
Expanded Access
Updated May 10, 2022
Expanded Access for Relatlimab
NCT05170659
No longer available
Expanded Access
Updated Apr 28, 2022
Expanded Access for ACE-011
NCT03724227
No longer available
Expanded Access
Updated Jul 17, 2020
Expanded Access to ABBV-706
NCT07310277
Available
Expanded Access
Updated Jan 29, 2026
Expanded Access for Apixaban
NCT05187286
Available
Expanded Access
Updated Mar 18, 2022
A Blinded Study Comparing the Safety and Efficacy of a Fully Human Anti-IL8 Monoclonal Antibody (ABX-IL8) to Placebo in Patients With Chronic Bronchitis and COPD
NCT00035828
Completed
Interventional
Phase 2
Updated Jun 24, 2005
Expanded Access for Anti-IL8 | NCT05210894 | Trialant
Save
Share
No longer available
Expanded Access
Updated May 16, 2022
Expanded Access for Anti-IL8
ClinicalTrials.gov ID
NCT05210894
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY
Overall Status
No longer available
Study Type
Expanded Access
Last Update Posted
May 16, 2022
Actual
Brief Summary
This is an expanded access designed to provide access to Anti-IL8 for eligible participants.
No conditions
There are no conditions for this study.
Anti-IL8
Ages Eligible for Study
Child (0-17)
Adult (18-64)
Older Adult (65+)
Sexes Eligible for Study
No data available
Accepts Healthy Volunteers
No data available
Eligibility Criteria
No data available
No design
There is no design for this study.
No central contacts
There are no central contacts for this study.
No locations
There are no locations for this study.
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY